Drug Interactions, Pharmacogenetics and the YouScript clinical decision support tool

Date of Presentation: 
Wednesday, October 28, 2015
2015 Fall
Research Focus: 

Abstract - Optimizing commonly prescribed drug treatments is challenging because of the prevalence of genetic variation in drug metabolizing enzymes and the frequency of multiple interactions between drugs and genes. The talk will introduce the medication interaction landscape and computational approaches to evaluating pharmacogenetic impact on patient drug regimens. We will describe some of the challenging problems we face, both in terms of modelling as well as algorithmic complexity involved in solving these problems.
Rajeev Pany, Director of Software Engineering - Pany joined Genelex in 2012 as the Director of Software Development. Pany manages the software development and architect teams, ensuring the accessibility, speed, and utility of the YouScript Personalized Prescribing software. Prior to Genelex, Pany was Director of Product Development at i2 Technologies and Engineering Director of Healthcare Applications at Net.Orange. Pany holds a Master of Science degree in mechanical engineering (neural networks/artificial intelligence/optimization) from the University of Texas at Austin, and a Bachelor of Science degree in Mechanical Engineering from Indian Institute of Technology at Madras, India.
Howard Coleman, CEO - Coleman co-founded Genelex in 1987 and currently serves as Chairman and CEO. He is leading the company to improve prescription drug treatment outcomes by application of the YouScript Precision Rx System consisting of the YouScript risk management software and DNA Drug Sensitivity Testing. He has also served as a member of the Washington State Board of Health Genetics Task Force and as faculty at the Institute for Science Training and Research. He has provided expert testimony in criminal cases, has written many publications and is an inventor on multiple patents. Coleman has a BS in Clinical Science and a BA in psychology and pursued graduate studies at the University of Washington and Fred Hutchinson Cancer Research Center.


Rajeev Pany, Howard Coleman
Speaker affiliation: